Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.39 -0.24 (-0.48%)

Streaming Delayed Price Updated: 9:49 AM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

39 40 Next >

Monkeypox Plays Jockey For Position This Week

August 08, 2022

Via AB Newswire

Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China ↗

August 04, 2022

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

August 04, 2022

Sanofi's (NASDAQ:SNY) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 0.09% of...

Via Benzinga

How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak ... And The Next ↗

August 04, 2022

Siga stock more than tripled, emerging from under the radar to take on the outbreak.

Via Investor's Business Daily

Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity ↗

August 03, 2022

Via Benzinga

A Bearish Sign Appears On Sanofi's Chart ↗

August 03, 2022

If history is any guide, there may be trouble ahead for shares of Sanofi (NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Via Benzinga

Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain ↗

July 28, 2022

The company reported more than 40% growth for Dupixent in the second quarter.

Via Investor's Business Daily

Sanofi Raises Annual Guidance On Upbeat Q2 Performance ↗

July 28, 2022

Via Benzinga

Daily Stock Analysis: Sanofi S.A. ↗

July 19, 2022

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris.

Via Talk Markets

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

3-D Portfolio: Discounts, Diversification, And Dividends ↗

July 31, 2022

When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can...

Via Talk Markets

Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking ↗

July 30, 2022

CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...

Via Talk Markets

Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients ↗

July 11, 2022

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea ↗

July 28, 2022

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran

Via Benzinga

Earnings Outlook For Sanofi ↗

July 27, 2022

Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an...

Via Benzinga

Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product ↗

July 25, 2022

Via Benzinga

Earnings Scheduled For July 28, 2022 ↗

July 28, 2022

Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.

Via Benzinga

Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform ↗

July 25, 2022

Via Benzinga

Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace ↗

July 24, 2022

Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies.

Via Benzinga

Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options ↗

July 20, 2022

Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.

Via Benzinga

Analyzing Sanofi's Short Interest ↗

July 19, 2022

Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of...

Via Benzinga

Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement ↗

July 19, 2022

CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.

Via InvestorPlace

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine ↗

July 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years ↗

July 14, 2022

Via Benzinga

Sanofi Offloads 17 Products To Neuraxpharm ↗

July 13, 2022

Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis ↗

July 11, 2022

Via Benzinga

Biotech Stocks To Watch And Pharma Industry News ↗

July 08, 2022

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Via Investor's Business Daily

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.